abstract: OBJECTIVE: To evaluate the effectiveness of a combined Traditional Chinese Medicine (TCM) therapy versus conventional treatment on @entity2 . METHODS: One hundred twenty outpatients with mild and moderate @entity2 were randomly divided into a @entity1 ( @entity1 ) and a brace group (CG). @entity1 @entity0 underwent Daoyin, Tuina, and acupotomology therapies. CG @entity0 were treated with a Milwaukee brace. Each @entity0 's Cobb angle was measured after 12 and 24 months of treatment, and pulmonary function was determined after 12 months of treatment. Average electromyogram (AEMG) ratio of the surface electromyogram was measured after 6 and 12 months of treatment and followed-up after 18 and 24 months. RESULTS: The Cobb angle significantly decreased in both groups after 12 months of treatment compared with before treatment (P< 0.05). The percentages of original Cobb angle in @entity1 and CG were 51.4% and 47.8% (P > 0.05) after 12 months and 62.5% and 34.7% (P < 0.05) after 24 months, respectively. Pulmonary function significantly improved after 12 months in @entity1 (P < 0.05) but significantly decreased in CG (P < 0.05). The AEMG ratio was significantly lower (P < 0.01) and tended to remain at 1 after stopping treatment in @entity1 , but increased in CG (P < 0.05). CONCLUSION: TCM combined therapy can prevent the progression of @entity3 . The AEMG ratio is a promising index that could replace radiography in the evaluation of treatment effect and progression in @entity3 .

title: Effect of a Traditional Chinese Medicine combined therapy on XXXX : a randomized controlled trial.

answer: @entity2


abstract: Lipoprotein lipase ( @entity7 ) is a key enzyme in lipoprotein and adipocyte metabolism. Defects in @entity7 can lead to @entity4 and the subsequent development of @entity2 . The mechanisms of regulation of this enzyme are complex and may occur at multiple levels of gene expression. Because the 3'-untranslated region (UTR) is involved in @entity7 translational regulation, @entity0 were generated with adipose tissue expression of an @entity7 construct either with or without the proximal 3'-UTR and driven by the aP2 promoter. Both transgenic @entity0 colonies were viable and expressed the transgene, resulting in a 2-fold increase in @entity7 activity in white adipose tissue. Neither @entity0 colony exhibited any obvious phenotype in terms of body weight, plasma lipids, @entity1 , and non-esterified @entity3 levels. In the @entity0 expressing @entity6 with an intact 3'-UTR, @entity6 mRNA expression approximately paralleled @entity6 activity. However in the @entity0 without the proximal 3'-UTR, @entity6 mRNA was low in the setting of large amounts of @entity6 protein and @entity7 activity. In previous studies, the 3'-UTR of @entity7 was critical for the inhibitory effects of constitutively expressed hormones, such as thyroid hormone and @entity5 . Therefore, these data suggest that the absence of the 3'-UTR results in a translationally unrepressed @entity7 , resulting in a moderate overexpression of adipose @entity7 activity.

title: XXXX expressing lipoprotein lipase in adipose tissue. Absence of the proximal 3'-untranslated region causes translational upregulation.

answer: @entity0


abstract: STUDY OBJECTIVE: To determine the feasibility of rapid pleurodesis in @entity0 with @entity4 in order to reduce hospital length of stay in @entity0 with a limited life expectancy. DESIGN: Prospective case series. SETTING: Two university hospital programs. @entity0 : Thirty-eight @entity0 with symptomatic @entity2 associated with @entity1 . INTERVENTIONS: @entity5 catheter was inserted percutaneously into the pleural space after radiographic confirmation of free fluid by lateral decubitus views. Following radiographic confirmation of complete fluid evacuation, a sclerosing agent (ie, talc slurry or @entity3 ) was instilled into the pleural space. This was accomplished within 2 h of chest tube insertion, unless the tube was inserted in the evening or if the lung was trapped. After clamping the tube for 90 min, the pleural space was drained for 2 h, after which the chest tube was removed. The intervention was scored as "successful" if no radiographic evidence of fluid reaccumulation was noted at 4 weeks. A "partial successful" score indicated reaccumulation of fluid that did not produce symptoms and did not require repeat pleural drainage of any sort. All other outcomes were scored as "unsuccessful." MEASUREMENTS AND RESULTS: Forty chest tubes were inserted into 38 @entity0 . Four procedures revealed the presence of a trapped lung and did not result in any attempt at pleurodesis. Five @entity0 who received pleurodesis died in less than 1 month and therefore were not evaluable. Two @entity0 had technical problems with the chest tube and were not evaluable. Of the remaining 29 procedures, drainage procedures with pleurodesis were performed in 27 @entity0 , a complete response was seen in 14 @entity0 (48%), a partial response was seen in 9 @entity0 (31%), and 6 @entity0 (21%) did not respond to pleurodesis. Chemical pleurodesis was completed as an outpatient procedure in only two @entity0 . In one of these, the outcome was unsuccessful. In the remainder, insertion of the chest tube in the evening or additional medical problems necessitated hospital admission, but the entire procedure was completed within 24 h. CONCLUSIONS: Chemical pleurodesis can be accomplished with good results in < 24 h in the majority of @entity0 with @entity4 .

title: Rapid pleurodesis for XXXX .

answer: @entity4


abstract: OBJECTIVES: To study the difference between the disease-specific and excess mortality rate in the European Randomized Study of Screening for @entity2 section Rotterdam. METHODS: A total of 42,376 @entity0 were randomized to systematic screening or usual care. The excess number of @entity1 was defined as the difference between the observed number of @entity2 ( @entity2 ) @entity0 and the expected number of @entity1 up to 31 December 2006. The expected number was derived from mortality of all study @entity0 before a possible diagnosis with @entity2 . The disease-specific mortality rate was based on the number of @entity0 who died from @entity2 . The excess mortality rate based on the arm-specific excess number of @entity1 and the disease-specific mortality rate were compared between the two study arms. RESULTS: The overall mortality rate was not significantly different between the intervention and the control arms of the study: RR 1.02 (95% CI 0.98-1.07). The disease-specific mortality rate was 0.42 @entity0 per 1000 @entity0 -years in the intervention and 0.48 @entity0 per 1000 @entity0 -years in the control arm: RR 0.86 (95% CI 0.64-1.17). The excess mortality rate was 0.40 per 1000 @entity0 -years in the intervention arm and 0.61 @entity0 per 1000 @entity0 -years in the control arm, and the RR for excess mortality was 0.66 (95% CI 0.39-1.13). CONCLUSIONS: In contrast to the disease-specific mortality rates an increased difference in the excess mortality rates was observed between the two arms. This observation may be due to a systematic underestimation of the disease-specific @entity1 , and/or an additional disease-related mortality that is measured by an excess mortality analysis but not by a disease-specific mortality.

title: Disease-specific mortality may underestimate the total effect of XXXX screening.

answer: @entity2


abstract: @entity3 amoebae with an altered fbxA gene, which is thought to encode a component of an SCF E3 ubiquitin ligase, have defective regulation of cell type proportionality. In chimeras with wild-type cells, the mutant amoebae form mainly spores, leaving the construction of stalks to wild-type cells. To examine the role of fbxA and regulated proteolysis, we have recovered the promoter of fbxA and shown that it is expressed in a pattern resembling that of a prestalk-specific gene until late in development, when it is also expressed in developing spore cells. Because fbxA cells are developmentally deficient in pure culture, we were able to select suppressor mutations that promote sporulation of the original mutant. One suppressor mutation resides within the gene regA, which encodes a @entity1 ( @entity0 ) phosphodiesterase linked to an activating response regulator domain. In another suppressor, there has been a disruption of dhkA, a gene encoding a two-component @entity2 kinase known to influence @entity3 development. RegA appears precociously and in greater amounts in the fbxA mutant than in the wild type, but in an fbxA/dhkA double mutant, RegA is restored to wild-type levels. Because the basis of regA suppression might involve alterations in @entity0 levels during development, the concentrations of @entity0 in all strains were determined. The levels of @entity0 are relatively constant during multicellular development in all strains except the dhkA mutant, in which it is reduced at least sixfold. The level of @entity0 in the double mutant dhkA/fbxA is relatively normal. The levels of @entity0 in the various mutants do not correlate with spore formation, as would be expected on the basis of our present understanding of the signaling pathway leading to the induction of spores. Altered amounts of RegA and @entity0 early in the development of the mutants suggest that both fbxA and dhkA genes act earlier than previously thought.

title: Genetic interactions of the E3 ubiquitin ligase component FbxA with XXXX metabolism and a @entity2 kinase signaling pathway during @entity3 development.

answer: @entity1


abstract: @entity3 amoebae with an altered fbxA gene, which is thought to encode a component of an SCF E3 ubiquitin ligase, have defective regulation of cell type proportionality. In chimeras with wild-type cells, the mutant amoebae form mainly spores, leaving the construction of stalks to wild-type cells. To examine the role of fbxA and regulated proteolysis, we have recovered the promoter of fbxA and shown that it is expressed in a pattern resembling that of a prestalk-specific gene until late in development, when it is also expressed in developing spore cells. Because fbxA cells are developmentally deficient in pure culture, we were able to select suppressor mutations that promote sporulation of the original mutant. One suppressor mutation resides within the gene regA, which encodes a @entity1 ( @entity0 ) phosphodiesterase linked to an activating response regulator domain. In another suppressor, there has been a disruption of dhkA, a gene encoding a two-component @entity2 kinase known to influence @entity3 development. RegA appears precociously and in greater amounts in the fbxA mutant than in the wild type, but in an fbxA/dhkA double mutant, RegA is restored to wild-type levels. Because the basis of regA suppression might involve alterations in @entity0 levels during development, the concentrations of @entity0 in all strains were determined. The levels of @entity0 are relatively constant during multicellular development in all strains except the dhkA mutant, in which it is reduced at least sixfold. The level of @entity0 in the double mutant dhkA/fbxA is relatively normal. The levels of @entity0 in the various mutants do not correlate with spore formation, as would be expected on the basis of our present understanding of the signaling pathway leading to the induction of spores. Altered amounts of RegA and @entity0 early in the development of the mutants suggest that both fbxA and dhkA genes act earlier than previously thought.

title: Genetic interactions of the E3 ubiquitin ligase component FbxA with @entity1 metabolism and a XXXX kinase signaling pathway during @entity3 development.

answer: @entity2


abstract: @entity3 amoebae with an altered fbxA gene, which is thought to encode a component of an SCF E3 ubiquitin ligase, have defective regulation of cell type proportionality. In chimeras with wild-type cells, the mutant amoebae form mainly spores, leaving the construction of stalks to wild-type cells. To examine the role of fbxA and regulated proteolysis, we have recovered the promoter of fbxA and shown that it is expressed in a pattern resembling that of a prestalk-specific gene until late in development, when it is also expressed in developing spore cells. Because fbxA cells are developmentally deficient in pure culture, we were able to select suppressor mutations that promote sporulation of the original mutant. One suppressor mutation resides within the gene regA, which encodes a @entity1 ( @entity0 ) phosphodiesterase linked to an activating response regulator domain. In another suppressor, there has been a disruption of dhkA, a gene encoding a two-component @entity2 kinase known to influence @entity3 development. RegA appears precociously and in greater amounts in the fbxA mutant than in the wild type, but in an fbxA/dhkA double mutant, RegA is restored to wild-type levels. Because the basis of regA suppression might involve alterations in @entity0 levels during development, the concentrations of @entity0 in all strains were determined. The levels of @entity0 are relatively constant during multicellular development in all strains except the dhkA mutant, in which it is reduced at least sixfold. The level of @entity0 in the double mutant dhkA/fbxA is relatively normal. The levels of @entity0 in the various mutants do not correlate with spore formation, as would be expected on the basis of our present understanding of the signaling pathway leading to the induction of spores. Altered amounts of RegA and @entity0 early in the development of the mutants suggest that both fbxA and dhkA genes act earlier than previously thought.

title: Genetic interactions of the E3 ubiquitin ligase component FbxA with @entity1 metabolism and a @entity2 kinase signaling pathway during XXXX development.

answer: @entity3


abstract: Twenty-four @entity0 , ten of whom had an @entity2 due to @entity7 -resistant, @entity8 -sensitive bacteria, were treated with @entity8 . A full clinical success was obtained in sixteen cases (13 @entity6 , nine of them due to @entity7 -resistant, @entity8 -sensitive @entity3 , two @entity2 and one @entity1 ). Four @entity0 were improved (1 bronchiectasis, 3 @entity5 ), three were unassessable and one failure occurred with a staphylococcal urinary tract @entity2 . A pharmacokinetic study was performed in three newborns (under three months) and ten @entity0 (mean age 3 years). @entity8 was administered as four daily 30-min iv infusions. The mean dosage used in @entity0 under three months was 225 mg/kg/d @entity7 and 9 mg/kg/d @entity4 . In @entity0 older than three months of age the mean dosage was 250 mg/kg/d @entity7 and 16 mg/kg/d @entity4 . The pharmacokinetic results demonstrated similar serum concentrations of @entity7 to those in earlier studies, and serum concentrations of @entity4 of 3.1 +/- 0.63 mg/l and 2.18 +/- 0.17 mg/ @entity9 h respectively after infusion in newborns. For @entity0 , at the same times, the serum levels were respectively 2.3 +/- 0.9 mg/l and 1.4 +/- 0.9 mg/l. The peak serum concentrations of @entity4 were the same in the two groups of dosages (4.7 mg/l), but the half-lives of @entity4 were 1.1 h in @entity0 older than three months and 1.8 h in @entity0 younger than 3 months. The tolerance was good. @entity8 may be useful as a first line antibiotic in infections in hospitalized @entity0 in the dosage described, as three or four injections daily, according to the age and the severity of the disease.

title: Efficacy and pharmacokinetics of XXXX in paediatric infections.

answer: @entity8


abstract: UNASSIGNED: Six pigment-grade (pg) or ultrafine (uf)/nanoscale (anatase and/or rutile) @entity4 ( @entity3 ) particulates were evaluated for in  vivo genotoxicity (OECD 474 Guidelines) in male and female @entity0 by two different laboratories. All test materials were robustly characterized. The BET surface areas of the pg and uf samples ranged from 7 to 17  m(2)/g and 50 to 82  m(2)/g respectively. The materials were assessed for induction of micronuclei and @entity1 in bone marrow by analyzing peripheral blood reticulocytes (RETs) by flow cytometry. Single oral gavage doses of 500, 1000 or 2000  mg/kg body weight (bw) of each material were implemented with concurrent negative (water) and positive controls ( @entity2 ). Approximately 48 and 72  h after exposure, blood samples were collected and 20,000 RETs per animal were analyzed. For each of the six tests, there were no biologically or toxicologically relevant increases in the micronucleated @entity5 frequency in any @entity3 exposed group at either time point at any dose level. In addition, there were a lack of biologically relevant decreases in %RETs among total erythrocytes. All six @entity3 test substances were negative for in  vivo genotoxicity effects; however, it is noted that the exposure to target tissues was likely negligible. One pigment grade and one ultrafine material each were evaluated for potential systemic exposure/uptake from the gastrointestinal tract by analysis of @entity3 into blood and liver. No significant increases in @entity3 over controls were measured in blood (48 or 72  h) or liver (72  h) following exposures to 2000  mg/kg bw @entity3 . These data indicate that there was no absorption of the test material from the gastrointestinal tract into the blood circulation and the lack of genotoxic effects is therefore attributed to a lack of exposure due to the inability of the test material to migrate from the gastrointestinal tract into the blood and then into target tissues.

title: In  vivo micronucleus studies with 6 XXXX materials (3  pigment-grade _ 3 nanoscale) in orally-exposed @entity0 .

answer: @entity4


abstract: UNASSIGNED: Six pigment-grade (pg) or ultrafine (uf)/nanoscale (anatase and/or rutile) @entity4 ( @entity3 ) particulates were evaluated for in  vivo genotoxicity (OECD 474 Guidelines) in male and female @entity0 by two different laboratories. All test materials were robustly characterized. The BET surface areas of the pg and uf samples ranged from 7 to 17  m(2)/g and 50 to 82  m(2)/g respectively. The materials were assessed for induction of micronuclei and @entity1 in bone marrow by analyzing peripheral blood reticulocytes (RETs) by flow cytometry. Single oral gavage doses of 500, 1000 or 2000  mg/kg body weight (bw) of each material were implemented with concurrent negative (water) and positive controls ( @entity2 ). Approximately 48 and 72  h after exposure, blood samples were collected and 20,000 RETs per animal were analyzed. For each of the six tests, there were no biologically or toxicologically relevant increases in the micronucleated @entity5 frequency in any @entity3 exposed group at either time point at any dose level. In addition, there were a lack of biologically relevant decreases in %RETs among total erythrocytes. All six @entity3 test substances were negative for in  vivo genotoxicity effects; however, it is noted that the exposure to target tissues was likely negligible. One pigment grade and one ultrafine material each were evaluated for potential systemic exposure/uptake from the gastrointestinal tract by analysis of @entity3 into blood and liver. No significant increases in @entity3 over controls were measured in blood (48 or 72  h) or liver (72  h) following exposures to 2000  mg/kg bw @entity3 . These data indicate that there was no absorption of the test material from the gastrointestinal tract into the blood circulation and the lack of genotoxic effects is therefore attributed to a lack of exposure due to the inability of the test material to migrate from the gastrointestinal tract into the blood and then into target tissues.

title: In  vivo micronucleus studies with 6 @entity4 materials (3  pigment-grade _ 3 nanoscale) in orally-exposed XXXX .

answer: @entity0


abstract: OBJECTIVE: To restore islet function in @entity0 whose @entity1 subjected them to frequent dangerous episodes of hypoglycemic unawareness, and to determine whether multiple transplants are always required to achieve @entity2 independence. SUMMARY BACKGROUND DATA: The recent report by the Edmonton group documenting restoration of @entity2 independence by islet transplantation in seven consecutive @entity0 with type 1 @entity1 differed from previous worldwide experience of only sporadic success. In the Edmonton @entity0 , the transplanted islet mass critical for success was approximately more than 9,000 IEq/kg of recipient body weight and required two or three separate transplants of islets isolated from two to four cadaveric donors. Whether the success of the Edmonton group can be recapitulated by others, and whether repeated transplants using multiple donors will be a universal requirement for success have not been reported. METHODS: The authors report their treatment with islet transplantation of nine @entity0 whose labile type 1 @entity1 was characterized by frequent episodes of @entity3 . RESULTS: In each of the seven @entity0 who have completed the treatment protocol (i.e., one or if necessary a second islet transplant), @entity2 independence has been achieved. In five of the seven @entity0 only a single infusion of islets was required. To date, only one recipient has subsequently lost graft function, after an initially successful transplant. This @entity0 suffered recurrent @entity4 9 months after the transplant. CONCLUSIONS: This report confirms the efficacy of the Edmonton immunosuppressive regimen and indicates that @entity2 independence can often be achieved by a single transplant of sufficient islet mass.

title: XXXX independence following isolated islet transplantation and single islet infusions.

answer: @entity2


abstract: A randomized two-stage, phase II study was conducted to assess the antitumor activity of two different schedules of topotecan in the treatment of @entity1 ( @entity3 ) in chemotherapy-naive @entity0 . A total of 40 eligible @entity0 were randomized to receive either the daily schedule, with topotecan being administered intravenously at 1.5 mg/m2 daily for 5 days every 3 weeks, or the continuous-infusion schedule, with topotecan administered intravenously at a dosage of 1.3 mg/m2 per day over 72 hours every 4 weeks. Randomization to the continuous-infusion schedule was discontinued due to inactivity, and an additional 20 @entity0 were treated on the daily schedule. @entity0 received an average of 5 courses (range: 1-13) of the daily schedule compared to an average of 2 courses (range: 1-7) of the continuous-infusion schedule (p < 0.01). Confirmed response rates for the daily and continuous-infusion schedules are 62.5% (90% CI: 49-75%) and 15% (90% CI: 1-29%), respectively. @entity2 was predominantly hematologic with 92% (55/60) having greater than or equal to grade III @entity6 and 58% (35/60) reporting greater than or equal to grade III @entity7 for both IV schedules. @entity2 was very mild, with only 10% (6/60) @entity0 experiencing grade IV @entity2 . One @entity0 died of @entity4 on the continuous-infusion arm. Median times to progression for the daily and continuous-infusion schedules are 5 months (90% CI: 4.4-7.2) and 2 months (90% CI: 1.1-2.1), respectively. Estimated 1-year survival rates for @entity0 receiving daily and continuous-infusion schedules are 63% (90% CI: 51-76%) and 55% (90% CI: 39-77%), respectively. Fifty percent (30/60) of @entity0 received second-line therapy with @entity8 and @entity5 . Forty-three percent (13/30) of @entity0 who received second-line therapy achieved a confirmed response. Topotecan showed significant activity in the treatment of extensive stage @entity3 when administered as a brief daily IV repeated every 3 weeks.

title: Randomized phase II study of daily versus continuous-infusion schedules of topotecan in the treatment of XXXX .

answer: @entity1


abstract: Some degree of peripheral @entity1 occurs in up to 20% of @entity0 treated with @entity3 (Gemzar). The @entity1 is typically mild, requiring discontinuation of the drug in less than 1% of @entity0 . Most @entity0 require no therapy. However, in cases of peripheral @entity1 , grade II or higher, suspension of @entity3 and treatment with @entity4 are often necessary, and permanent discontinuation of @entity3 may be required on occasion. We have identified 15 cases of peripheral @entity1 , grade II or greater, developing in @entity0 receiving @entity3 chemotherapy at Memorial Sloan-Kettering Cancer Center. The diagnosis was made based on temporal association with drug administration, and exclusion of other potential acute causes of @entity1 including @entity2 and @entity5 . The 15 @entity0 in this series represent less than 1% of all @entity0 treated with @entity3 at this institution over the same time period. @entity3 was immediately discontinued at the time of the onset of @entity1 in 7 of the 15 @entity0 due to severity of the symptoms. Thirteen of the 15 @entity0 in this case series had experienced peripheral @entity1 previously, and 6 had active low-grade @entity1 at the time the @entity3 was first administered. @entity0 receiving @entity3 should be advised of this potential complication and urged to promptly report its development so that comorbid conditions can be excluded and proper supportive measures initiated. @entity0 predisposed to peripheral @entity1 from some other cause may be at increased risk for developing severe peripheral @entity1 with @entity3 .

title: XXXX -induced peripheral @entity1 : report on 15 cases and review of the literature.

answer: @entity3


abstract: Some degree of peripheral @entity1 occurs in up to 20% of @entity0 treated with @entity3 (Gemzar). The @entity1 is typically mild, requiring discontinuation of the drug in less than 1% of @entity0 . Most @entity0 require no therapy. However, in cases of peripheral @entity1 , grade II or higher, suspension of @entity3 and treatment with @entity4 are often necessary, and permanent discontinuation of @entity3 may be required on occasion. We have identified 15 cases of peripheral @entity1 , grade II or greater, developing in @entity0 receiving @entity3 chemotherapy at Memorial Sloan-Kettering Cancer Center. The diagnosis was made based on temporal association with drug administration, and exclusion of other potential acute causes of @entity1 including @entity2 and @entity5 . The 15 @entity0 in this series represent less than 1% of all @entity0 treated with @entity3 at this institution over the same time period. @entity3 was immediately discontinued at the time of the onset of @entity1 in 7 of the 15 @entity0 due to severity of the symptoms. Thirteen of the 15 @entity0 in this case series had experienced peripheral @entity1 previously, and 6 had active low-grade @entity1 at the time the @entity3 was first administered. @entity0 receiving @entity3 should be advised of this potential complication and urged to promptly report its development so that comorbid conditions can be excluded and proper supportive measures initiated. @entity0 predisposed to peripheral @entity1 from some other cause may be at increased risk for developing severe peripheral @entity1 with @entity3 .

title: @entity3 -induced peripheral XXXX : report on 15 cases and review of the literature.

answer: @entity1


abstract: OBJECTIVE: To quantitatively evaluate a dual-modality treatment that combines autologous structural fat grafting and @entity2 ( @entity1 ) laser resurfacing for perioral and lower face rejuvenation. METHOD: Retrospective review of @entity0 undergoing rejuvenation by a single surgeon between 2005 and 2009. A blinded expert rated photographs on three scales, each with a range of 1 (no abnormality) to 5 (severe abnormality): (i) perioral fine rhytids; (ii) deep folds; and (iii) pigmentary or cutaneous abnormalities. Within-subject comparisons were generated. Results were correlated with skin type (Fitzpatrick) and baseline photodamage (Glogau). A test for effect of adjunctive procedures was performed. RESULTS: Seventeen @entity0 were included (all female, mean age 61 years). Significant postoperative improvement was noted for perioral fine rhytids (3.1 to 1.7, p < 0.0001); deep folds (3.4 to 2.0, p < 0.00001); and pigmentation (2.5 to 1.9, p = 0.02). Fitzpatrick skin type was inversely correlated with improvement in pigmentation scores (r = -0.78), while the Glogau score correlated with improvement of fine rhytids (r = 0.76). No significant effect of adjunctive procedures was found. No complications occurred, though fat grafts resorbed in one @entity0 . CONCLUSIONS: Concurrent structural fat grafting and @entity1 resurfacing result in quantifiable improvement of perioral and lower face aesthetics in relation to baseline characteristics and independent of adjunctive surgical procedures.

title: Concurrent structural fat grafting and XXXX laser resurfacing for perioral and lower face rejuvenation.

answer: @entity2


abstract: PURPOSE: We describe a novel technique of laparoscopic @entity2 with intracorporeal ice slush during partial nephrectomy as well as clinical experience with the initial 12 @entity0 . MATERIALS AND METHODS: A total of 12 select @entity0 with an infiltrating @entity5 who were candidates for nephron sparing surgery underwent transperitoneal laparoscopic partial nephrectomy with @entity2 . An Endocatch II (United States Surgical Corp., Norwalk, Connecticut) bag was placed around the mobilized kidney and its drawstring was cinched around the intact renal hilum. The renal artery and vein were occluded en bloc with a Satinsky clamp. The bottom of the engaged bag was retrieved through a 12 mm port site and opened, and ice slush was introduced within the bag to completely surround the kidney. After @entity2 was achieved laparoscopic partial nephrectomy was performed by duplicating open surgical techniques. Renal parenchymal temperature was measured using a thermocouple needle in 5 @entity0 . Median @entity1 size was 3.2 cm (range 1.5 to 5.5), 6 @entity1 (50%) were central in location and an imperative indication for partial nephrectomy was present in 7 @entity0 (58%). RESULTS: All procedures were successfully completed laparoscopically without open conversion. Median time to deploy the bag around the kidney was 7 minutes (range 5 to 20), the median volume of ice slush introduced was 600 cc (range 300 to 750) and the time needed to insert the ice slush was 4 minutes (range 3 to 10). Median @entity4 was 200 cc, total @entity3 time was 43.5 minutes (range 25 to 55) and total operative time was 4.3 hours (range 3 to 5.5). Nadir renal parenchymal temperature was 5C to 19C and the mean decrease in systemic temperature was 0.6C. Histopathology confirmed @entity6 in 11 @entity0 (92%), of whom all had negative surgical margins. @entity7 occurred in 2 initial @entity0 , including partial bag slippage in 1 and Satinsky clamp malfunction in 1. Postoperatively renal scan confirmed a functioning ipsilateral kidney in all cases. CONCLUSIONS: To our knowledge we present the initial clinical report of laparoscopic @entity2 for partial nephrectomy. By replicating standard open surgical practice our intracorporeal ice slush technique has the potential to extend the scope of laparoscopic partial nephrectomy to more @entity5 .

title: Laparoscopic ice slush XXXX for partial nephrectomy: the initial experience.

answer: @entity2


abstract: MicroRNAs (miRNAs) are kind of small non-coding RNAs that negatively regulate gene expression at post-transcription level, and those non-coding RNAs appear to play a key role in tumorigenesis. The aim of this study was to investigate the biological role of @entity5 in @entity1 ( @entity1 ) cell lines. We identified @entity5 to be up-regulated in @entity1 specimens in comparison to matched normal tissues by microRNA microarray and RT-qPCR analysis (P < 0.05). Next, to explore the potential function of @entity5 , @entity1 cell lines K1 and @entity3 were transiently transfected with @entity5 mimics and inhibitor. Successful transfection being confirmed by RT-qPCR. Ectopic expression of @entity5 promoted proliferation and colony formation ability, and inhibited apoptosis of K1 and @entity3 cells, whereas down-regulated expression of @entity5 suppressed those functions when compared with the control cells. According to a computational prediction, @entity2 maybe a potential target of @entity5 . Luciferase assays revealed that @entity5 is directly targeted to both binding sites of @entity2 3'-untranslated region (3'-UTR) and suppressed the @entity2 expression, and subsequently inhibited the expression of @entity4 protein in @entity1 cells. Moreover, the expression of @entity2 had an inverse correlation with expression of @entity5 in @entity1 specimens by RT-qPCR and western blot analysis. The data from the present study demonstrated that @entity5 can promote proliferation, and inhibit apoptosis in @entity1 cell lines K1 and @entity3 , thus @entity5 may play an oncogenic role in @entity1 by inhibiting the @entity2 and regulating @entity0 / @entity2 / @entity4 pathway, and it may serve as a novel therapeutic target for miRNA-based @entity1 therapy.

title: MicroRNA-96 plays an oncogenic role by targeting @entity2 and regulating XXXX / @entity2 / @entity4 pathway in @entity1 cells.

answer: @entity0


abstract: MicroRNAs (miRNAs) are kind of small non-coding RNAs that negatively regulate gene expression at post-transcription level, and those non-coding RNAs appear to play a key role in tumorigenesis. The aim of this study was to investigate the biological role of @entity5 in @entity1 ( @entity1 ) cell lines. We identified @entity5 to be up-regulated in @entity1 specimens in comparison to matched normal tissues by microRNA microarray and RT-qPCR analysis (P < 0.05). Next, to explore the potential function of @entity5 , @entity1 cell lines K1 and @entity3 were transiently transfected with @entity5 mimics and inhibitor. Successful transfection being confirmed by RT-qPCR. Ectopic expression of @entity5 promoted proliferation and colony formation ability, and inhibited apoptosis of K1 and @entity3 cells, whereas down-regulated expression of @entity5 suppressed those functions when compared with the control cells. According to a computational prediction, @entity2 maybe a potential target of @entity5 . Luciferase assays revealed that @entity5 is directly targeted to both binding sites of @entity2 3'-untranslated region (3'-UTR) and suppressed the @entity2 expression, and subsequently inhibited the expression of @entity4 protein in @entity1 cells. Moreover, the expression of @entity2 had an inverse correlation with expression of @entity5 in @entity1 specimens by RT-qPCR and western blot analysis. The data from the present study demonstrated that @entity5 can promote proliferation, and inhibit apoptosis in @entity1 cell lines K1 and @entity3 , thus @entity5 may play an oncogenic role in @entity1 by inhibiting the @entity2 and regulating @entity0 / @entity2 / @entity4 pathway, and it may serve as a novel therapeutic target for miRNA-based @entity1 therapy.

title: MicroRNA-96 plays an oncogenic role by targeting XXXX and regulating @entity0 / @entity2 / @entity4 pathway in @entity1 cells.

answer: @entity2


abstract: MicroRNAs (miRNAs) are kind of small non-coding RNAs that negatively regulate gene expression at post-transcription level, and those non-coding RNAs appear to play a key role in tumorigenesis. The aim of this study was to investigate the biological role of @entity5 in @entity1 ( @entity1 ) cell lines. We identified @entity5 to be up-regulated in @entity1 specimens in comparison to matched normal tissues by microRNA microarray and RT-qPCR analysis (P < 0.05). Next, to explore the potential function of @entity5 , @entity1 cell lines K1 and @entity3 were transiently transfected with @entity5 mimics and inhibitor. Successful transfection being confirmed by RT-qPCR. Ectopic expression of @entity5 promoted proliferation and colony formation ability, and inhibited apoptosis of K1 and @entity3 cells, whereas down-regulated expression of @entity5 suppressed those functions when compared with the control cells. According to a computational prediction, @entity2 maybe a potential target of @entity5 . Luciferase assays revealed that @entity5 is directly targeted to both binding sites of @entity2 3'-untranslated region (3'-UTR) and suppressed the @entity2 expression, and subsequently inhibited the expression of @entity4 protein in @entity1 cells. Moreover, the expression of @entity2 had an inverse correlation with expression of @entity5 in @entity1 specimens by RT-qPCR and western blot analysis. The data from the present study demonstrated that @entity5 can promote proliferation, and inhibit apoptosis in @entity1 cell lines K1 and @entity3 , thus @entity5 may play an oncogenic role in @entity1 by inhibiting the @entity2 and regulating @entity0 / @entity2 / @entity4 pathway, and it may serve as a novel therapeutic target for miRNA-based @entity1 therapy.

title: MicroRNA-96 plays an oncogenic role by targeting @entity2 and regulating @entity0 / XXXX / @entity4 pathway in @entity1 cells.

answer: @entity2


abstract: MicroRNAs (miRNAs) are kind of small non-coding RNAs that negatively regulate gene expression at post-transcription level, and those non-coding RNAs appear to play a key role in tumorigenesis. The aim of this study was to investigate the biological role of @entity5 in @entity1 ( @entity1 ) cell lines. We identified @entity5 to be up-regulated in @entity1 specimens in comparison to matched normal tissues by microRNA microarray and RT-qPCR analysis (P < 0.05). Next, to explore the potential function of @entity5 , @entity1 cell lines K1 and @entity3 were transiently transfected with @entity5 mimics and inhibitor. Successful transfection being confirmed by RT-qPCR. Ectopic expression of @entity5 promoted proliferation and colony formation ability, and inhibited apoptosis of K1 and @entity3 cells, whereas down-regulated expression of @entity5 suppressed those functions when compared with the control cells. According to a computational prediction, @entity2 maybe a potential target of @entity5 . Luciferase assays revealed that @entity5 is directly targeted to both binding sites of @entity2 3'-untranslated region (3'-UTR) and suppressed the @entity2 expression, and subsequently inhibited the expression of @entity4 protein in @entity1 cells. Moreover, the expression of @entity2 had an inverse correlation with expression of @entity5 in @entity1 specimens by RT-qPCR and western blot analysis. The data from the present study demonstrated that @entity5 can promote proliferation, and inhibit apoptosis in @entity1 cell lines K1 and @entity3 , thus @entity5 may play an oncogenic role in @entity1 by inhibiting the @entity2 and regulating @entity0 / @entity2 / @entity4 pathway, and it may serve as a novel therapeutic target for miRNA-based @entity1 therapy.

title: MicroRNA-96 plays an oncogenic role by targeting @entity2 and regulating @entity0 / @entity2 / @entity4 pathway in XXXX cells.

answer: @entity1


abstract: MicroRNAs (miRNAs) are kind of small non-coding RNAs that negatively regulate gene expression at post-transcription level, and those non-coding RNAs appear to play a key role in tumorigenesis. The aim of this study was to investigate the biological role of @entity5 in @entity1 ( @entity1 ) cell lines. We identified @entity5 to be up-regulated in @entity1 specimens in comparison to matched normal tissues by microRNA microarray and RT-qPCR analysis (P < 0.05). Next, to explore the potential function of @entity5 , @entity1 cell lines K1 and @entity3 were transiently transfected with @entity5 mimics and inhibitor. Successful transfection being confirmed by RT-qPCR. Ectopic expression of @entity5 promoted proliferation and colony formation ability, and inhibited apoptosis of K1 and @entity3 cells, whereas down-regulated expression of @entity5 suppressed those functions when compared with the control cells. According to a computational prediction, @entity2 maybe a potential target of @entity5 . Luciferase assays revealed that @entity5 is directly targeted to both binding sites of @entity2 3'-untranslated region (3'-UTR) and suppressed the @entity2 expression, and subsequently inhibited the expression of @entity4 protein in @entity1 cells. Moreover, the expression of @entity2 had an inverse correlation with expression of @entity5 in @entity1 specimens by RT-qPCR and western blot analysis. The data from the present study demonstrated that @entity5 can promote proliferation, and inhibit apoptosis in @entity1 cell lines K1 and @entity3 , thus @entity5 may play an oncogenic role in @entity1 by inhibiting the @entity2 and regulating @entity0 / @entity2 / @entity4 pathway, and it may serve as a novel therapeutic target for miRNA-based @entity1 therapy.

title: MicroRNA-96 plays an oncogenic role by targeting @entity2 and regulating @entity0 / @entity2 / XXXX pathway in @entity1 cells.

answer: @entity4


abstract: PURPOSE: Post-radical prostatectomy @entity1 occurs in 0.5% to 87% of @entity0 . This condition may be attributable to intrinsic @entity2 , and/or detrusor abnormalities. Previous studies of pelvic floor exercise (PFE) for improving @entity1 have shown mixed results. We determined whether preoperative and early postoperative biofeedback enhanced PFE with a dedicated physical therapist would improve the early return of @entity1 . MATERIALS AND METHODS: A total of 38 consecutive @entity0 undergoing radical prostatectomy from November 1998 to June 1999 were randomly assigned to a control or a treatment group. The treatment group of 19 @entity0 was referred to physical therapy and underwent PFE sessions before and after surgery. @entity0 were also given instructions to continue PFE at home twice daily after surgery. The control group of 19 @entity0 underwent surgery without formal PFE instructions. All @entity0 completed postoperative @entity1 at 6, 12, 16, 20, 28 and 52 weeks. @entity1 was measured by the number of pads used with 0 or 1 daily defined as continence. RESULTS: Overall 66% of the @entity0 were continent at 16 weeks. A greater fraction of the treatment group regained urinary continence earlier compared with the control group at 12 weeks (p <0.05). Three control and 2 treatment group @entity0 had severe @entity1 (greater than 3 pads daily) at 16 and 52 weeks. Of all @entity0 82% regained continence by 52 weeks. CONCLUSIONS: PFE therapy instituted prior to radical prostatectomy aids in the earlier achievement of @entity1 . However, PFE has limited benefit in @entity0 with severe @entity1 16 weeks after surgery. There is a minimal long-term benefit of PFE training since continence rates at 1 year were similar in the 2 groups.

title: The role of pelvic floor exercises on XXXX .

answer: @entity1


abstract: OBJECTIVE: Since the introduction of a preformed silo to the authors' practice in 1997, there has been a decrease in primary closure of @entity3 . To clarify the impact of this change, the authors reviewed their results over the past 10 years. METHODS: From @entity0 records, the authors abstracted the closure method, mechanical ventilation days, time to full feeds, mechanical and infectious complications, and length of stay. The authors compared groups using the Student t test and the Mann-Whitney test, as appropriate. RESULTS: Between 1993 and the present, 124 @entity0 were identified. Between 1993 and 1997, 38 @entity0 presented with @entity3 . Thirty-two (84.2%) closures were primary and six (18.8%) were staged. After 1997, the authors treated 80 @entity0 with @entity3 . There were 27 (33.8%) primary and 53 (66.2%) staged closures. Six @entity0 with other lethal anomalies were excluded. Length of stay and ventilator days were higher for the staged closure group, but @entity2 and mechanical complications were less common in the staged closure group. The time to full feeds did not differ. CONCLUSIONS: A lower incidence of @entity2 and complications related to @entity4 has made staged closure of @entity3 more common in the authors' practice. While it has resulted in a longer hospital stay, staged closure decreases the risk of long-term @entity1 and need for reoperation.

title: Evolution of staged versus primary closure of XXXX .

answer: @entity3


abstract: OBJECTIVE: To evaluate factors predictive of survival following curative resection for node-negative @entity3 . SUMMARY BACKGROUND DATA: Presence or absence of lymph node @entity1 is the most powerful predictor of survival following curative resection for @entity3 . Factors predictive of survival in node-negative @entity3 have not been clarified. METHODS: Histopathology and clinical outcome for all @entity0 undergoing R0 resections for @entity3 at a tertiary center between 1985 and 2001 were reviewed. RESULTS: Of 1,256 R0 resections performed, 507 (40%) were node-negative, 465 were T1-T3, and 317 of these were adequately staged, as defined by histologic evaluation of at least 15 lymph nodes. Median age was 67 years, and 62% were male. Forty percent had T1 @entity2 , 34% were T2, and 26% were T3. Median @entity2 size was 3 cm. Vascular invasion (VI) was present in 17% of @entity2 and @entity1 ( @entity1 ) in 31%. Extended (D2) lymphadenectomy was performed in 75% of cases. Five- and 10-year disease-specific survival rates were 79% and 67% respectively. Factors associated with poorer disease-specific survival on univariate analysis were male gender, serosal invasion, presence of VI, presence of @entity1 , and resection other than distal subtotal gastrectomy. On multivariate analysis, @entity1 was not an independent predictor of survival, but correlated directly with advancing T stage and @entity2 size. CONCLUSIONS: Serosal invasion and presence of VI are strong predictors of poor survival in this disease. @entity1 correlates with T stage and @entity2 size and may serve as a marker of advanced disease.

title: Biologic predictors of survival in node-negative XXXX .

answer: @entity3


abstract: @entity8 is a new antifolate that has shown activity in @entity5 -resistant @entity1 . @entity2 is an antimetabolite similar in structure to @entity7 with early studies demonstrating activity in a variety of @entity1 . It also has apparent synergistic activity with antifolates from initial work in @entity1 models. @entity4 is an antimicrotubule agent that has a wide spectrum of activity against a variety of solid @entity1 . The combination of @entity2 , @entity4 , and @entity8 was assessed in this phase I trial. Thirty @entity0 were enrolled. The starting doses were @entity8 25 mg orally twice daily (days 1-4, 15-18), @entity4 75 mg/m2 (days 1, 15), and @entity2 750 mg/m2 (days 1, 15), which then was escalated in a stepwise fashion. Four @entity0 achieved stable disease while on study, whereas one @entity0 with a poorly differentiated @entity1 achieved a partial response. The main @entity3 was myelosuppression. The maximum tolerated dose was thought to be @entity8 25 mg orally three times daily (days 1-4), @entity4 150 to 175 mg/m2 (days 1, 15), and @entity2 1,000 mg/m2 (days 1, 15). The combination of these new antifolates with @entity4 and @entity2 appears safe and should be considered for phase II trials in known @entity1 such as @entity6 .

title: XXXX , @entity4 , and @entity8 : a phase I study.

answer: @entity2


abstract: @entity8 is a new antifolate that has shown activity in @entity5 -resistant @entity1 . @entity2 is an antimetabolite similar in structure to @entity7 with early studies demonstrating activity in a variety of @entity1 . It also has apparent synergistic activity with antifolates from initial work in @entity1 models. @entity4 is an antimicrotubule agent that has a wide spectrum of activity against a variety of solid @entity1 . The combination of @entity2 , @entity4 , and @entity8 was assessed in this phase I trial. Thirty @entity0 were enrolled. The starting doses were @entity8 25 mg orally twice daily (days 1-4, 15-18), @entity4 75 mg/m2 (days 1, 15), and @entity2 750 mg/m2 (days 1, 15), which then was escalated in a stepwise fashion. Four @entity0 achieved stable disease while on study, whereas one @entity0 with a poorly differentiated @entity1 achieved a partial response. The main @entity3 was myelosuppression. The maximum tolerated dose was thought to be @entity8 25 mg orally three times daily (days 1-4), @entity4 150 to 175 mg/m2 (days 1, 15), and @entity2 1,000 mg/m2 (days 1, 15). The combination of these new antifolates with @entity4 and @entity2 appears safe and should be considered for phase II trials in known @entity1 such as @entity6 .

title: @entity2 , @entity4 , and XXXX : a phase I study.

answer: @entity8


abstract: @entity8 is a new antifolate that has shown activity in @entity5 -resistant @entity1 . @entity2 is an antimetabolite similar in structure to @entity7 with early studies demonstrating activity in a variety of @entity1 . It also has apparent synergistic activity with antifolates from initial work in @entity1 models. @entity4 is an antimicrotubule agent that has a wide spectrum of activity against a variety of solid @entity1 . The combination of @entity2 , @entity4 , and @entity8 was assessed in this phase I trial. Thirty @entity0 were enrolled. The starting doses were @entity8 25 mg orally twice daily (days 1-4, 15-18), @entity4 75 mg/m2 (days 1, 15), and @entity2 750 mg/m2 (days 1, 15), which then was escalated in a stepwise fashion. Four @entity0 achieved stable disease while on study, whereas one @entity0 with a poorly differentiated @entity1 achieved a partial response. The main @entity3 was myelosuppression. The maximum tolerated dose was thought to be @entity8 25 mg orally three times daily (days 1-4), @entity4 150 to 175 mg/m2 (days 1, 15), and @entity2 1,000 mg/m2 (days 1, 15). The combination of these new antifolates with @entity4 and @entity2 appears safe and should be considered for phase II trials in known @entity1 such as @entity6 .

title: @entity2 , XXXX , and @entity8 : a phase I study.

answer: @entity4


abstract: This study reports the University of Florida experience treating @entity4 with the goal of identifying the factors that predict favorable outcome. Between 1958 and June 1998, 51 @entity0 (aged 5-75 years) were diagnosed with pure @entity4 at the University of Florida. Histologic grade was anaplastic in 19 @entity0 , low-grade in 30 @entity0 , and unknown in one @entity0 . Twelve @entity0 were treated with surgery alone (10 with @entity1 ). Thirty-nine @entity0 underwent postoperative radiotherapy after surgery (plus chemotherapy in four @entity0 ). A biopsy was performed in 10 @entity0 , 40 underwent subtotal or gross total resection, and one had surgery of unknown extent. Thirteen @entity0 with a radiographic abnormality consistent with a @entity2 had the initiation of definitive treatment (i.e., surgery with or without radiotherapy) deferred for a median of 4.5 years before undergoing treatment for worsening symptoms or radiographic progression. Absolute survival for the entire group (51 @entity0 ) at 5, 10, and 20 years from the date of initial treatment was 61%, 37%, and 31%, respectively, and at 5, 10, and 20 years from the date of initial diagnosis was 65%, 43%, and 34%, respectively. No @entity0 died of intercurrent disease. Multivariate analysis for absolute survival from the time of initial treatment demonstrated young age (young @entity0 fared better than older @entity0 ) and size (<5 cm better than > or =5 cm) to be significant variables. No @entity0 under the age of 21 years (n = 8) at the time of diagnosis has died in this series. Deferring aggressive treatment did not alter survival. Multivariate analysis for favorable absolute survival based on the time from initial diagnosis demonstrated young age and presentation with @entity3 alone to be statistically significant for favorable outcomes. Approximately one third of @entity0 with @entity4 appear to be cured with aggressive treatment. Age is the most important predictor of long-term progression-free and absolute survival with young @entity0 (especially aged <21 years) doing much better than older @entity0 . Deferring aggressive treatment (surgery and/or radiation) until symptoms clearly indicate @entity1 progression does not compromise outcome for a select group of @entity0 who are diagnosed at a young age with a nonenhancing mass on MR and @entity3 as the lone presenting symptom.

title: XXXX : does deferring treatment compromise outcome?

answer: @entity4


abstract: Anti-silencing function1 ( @entity5 ) is an evolutionarily conserved histone chaperone. Studies in @entity0 and animals indicate that @entity5 proteins play important roles in various chromatin-based processes, including gene transcription, DNA replication and repair. While two genes encoding @entity5 homologues, @entity3 and @entity4 , are found in the @entity1 genome, their function has not been studied. Here we report that both @entity3 and @entity4 proteins bind histone H3, and are localized in the cytoplasm and the nucleus. Loss-of-function of either @entity3 or @entity4 did not show obvious defects, whereas simultaneous knockdown of both genes in the double mutant Atasf1ab drastically inhibited plant growth and caused abnormal vegetative and reproductive organ development. The Atasf1ab mutant plants exhibit cell number reduction, S-phase delay/arrest, and reduced polyploidy levels. Selective up-regulation of expression of a subset of genes, including those involved in S-phase checkpoints and the @entity2 gene at the G   -to-M transition, was observed in Atasf1ab. Furthermore, the Atasf1ab-triggered replication fork stalling constitutively activates the DNA damage checkpoint and repair genes, including ATM, ATR, @entity6 and @entity7 as well as several genes of the homologous recombination (HR) pathway but not genes of the non-homologous end joining (NHEJ) pathway. In spite of the activation of repair genes, an increased level of DNA damage was detected in Atasf1ab, suggesting that defects in the mutant largely exceed the available capacity of the repair machinery. Taken together, our study establishes crucial roles for the @entity3 and @entity4 genes in chromatin replication, maintenance of genome integrity and cell proliferation during plant development.

title: @entity1 homologues of the histone chaperone XXXX are crucial for chromatin replication and cell proliferation in plant development.

answer: @entity5


abstract: Anti-silencing function1 ( @entity5 ) is an evolutionarily conserved histone chaperone. Studies in @entity0 and animals indicate that @entity5 proteins play important roles in various chromatin-based processes, including gene transcription, DNA replication and repair. While two genes encoding @entity5 homologues, @entity3 and @entity4 , are found in the @entity1 genome, their function has not been studied. Here we report that both @entity3 and @entity4 proteins bind histone H3, and are localized in the cytoplasm and the nucleus. Loss-of-function of either @entity3 or @entity4 did not show obvious defects, whereas simultaneous knockdown of both genes in the double mutant Atasf1ab drastically inhibited plant growth and caused abnormal vegetative and reproductive organ development. The Atasf1ab mutant plants exhibit cell number reduction, S-phase delay/arrest, and reduced polyploidy levels. Selective up-regulation of expression of a subset of genes, including those involved in S-phase checkpoints and the @entity2 gene at the G   -to-M transition, was observed in Atasf1ab. Furthermore, the Atasf1ab-triggered replication fork stalling constitutively activates the DNA damage checkpoint and repair genes, including ATM, ATR, @entity6 and @entity7 as well as several genes of the homologous recombination (HR) pathway but not genes of the non-homologous end joining (NHEJ) pathway. In spite of the activation of repair genes, an increased level of DNA damage was detected in Atasf1ab, suggesting that defects in the mutant largely exceed the available capacity of the repair machinery. Taken together, our study establishes crucial roles for the @entity3 and @entity4 genes in chromatin replication, maintenance of genome integrity and cell proliferation during plant development.

title: XXXX homologues of the histone chaperone @entity5 are crucial for chromatin replication and cell proliferation in plant development.

answer: @entity1


abstract: PURPOSE: Although many aspects of ureteral physiology are well characterized, the exact mechanism of ureteral smooth muscle modulation has not been fully established. In other smooth muscle contractility is modulated by @entity3 ( @entity3 ). We determined the presence of a local ureteral @entity1 -angiotensin system and characterized the functional role of @entity3 in ureteral smooth muscle. MATERIALS AND METHODS: Reverse transcriptase-polymerase chain reaction was performed to determine the expression of @entity3 , @entity1 , angiotensin-converting enzyme and angiotensin receptor subtype 1 mRNA. The presence of @entity3 in ureteral tissue was determined by immunohistochemistry. @entity0 and @entity2 ureteral smooth muscle strips were suspended in tissue baths to determine the effect of the @entity3 receptor antagonist @entity4 on the frequency and amplitude of spontaneous ureteral contractions. Electrical field stimulation was performed before and after exposure to @entity4 . RESULTS: @entity3 , @entity1 , angiotensin-converting enzyme and angiotensin receptor subtype 1 mRNA expression was detected in @entity0 ureter. Immunoreactivity for @entity3 was demonstrated in smooth muscle bundles and blood vessels of the ureter. @entity4 decreased the amplitude and frequency of spontaneous ureteral contractions as well as the contractile response to electrical field stimulation in a dose dependent manner. CONCLUSIONS: Gene expression of @entity3 precursors and receptor, and localization of @entity3 in the ureter suggest the presence of a local @entity1 -angiotensin system in the ureter. The effect of @entity3 receptor antagonist on contractile responses suggests that @entity3 modulates ureteral smooth muscle contractile function. Therefore, a local @entity1 -angiotensin system may have an important role in ureteral function under physiological and pathological conditions.

title: Ureteral function is modulated by a local XXXX -angiotensin system.

answer: @entity1


abstract: @entity2 ( @entity3 ) with @entity6 (AMLEC) is a comparatively rare @entity4 that is recently recognized as a distinct entity and there are relatively few reported cases in the English-language literature. To date 19 cases of AMLEC have been reported in 2 case series and a few case reports. AMLEC has been described as a cystic variant of @entity3 . Herein we reported an AMLEC in a 25-year-old female @entity0 , and to the best of our knowledge this is the first case report of AMLEC in Chinese. She was incidentally found to have a kidney-occupying lesion during a routine medical examination for 1 month. CT examination demonstrated a @entity9 arising from right-kidney lower pole. The @entity0 underwent the partial nephrectomy. Histological examination of the @entity1 was composed of @entity6 , @entity8 and muscle-predominant @entity3 . Immunohistochemically, @entity6 were positive for CK but negative for ER, PR, @entity5 and HMB-45; the subepithelial stroma and muscle-predominant @entity3 were positive for ER, PR and HMB-45; the subepithelial stroma was negative for @entity7 , but muscle-predominant @entity3 was positive for @entity7 . The final histopathological diagnosis was AMLEC.

title: XXXX with @entity6 : a rare entity and review of literature.

answer: @entity2


abstract: @entity2 ( @entity3 ) with @entity6 (AMLEC) is a comparatively rare @entity4 that is recently recognized as a distinct entity and there are relatively few reported cases in the English-language literature. To date 19 cases of AMLEC have been reported in 2 case series and a few case reports. AMLEC has been described as a cystic variant of @entity3 . Herein we reported an AMLEC in a 25-year-old female @entity0 , and to the best of our knowledge this is the first case report of AMLEC in Chinese. She was incidentally found to have a kidney-occupying lesion during a routine medical examination for 1 month. CT examination demonstrated a @entity9 arising from right-kidney lower pole. The @entity0 underwent the partial nephrectomy. Histological examination of the @entity1 was composed of @entity6 , @entity8 and muscle-predominant @entity3 . Immunohistochemically, @entity6 were positive for CK but negative for ER, PR, @entity5 and HMB-45; the subepithelial stroma and muscle-predominant @entity3 were positive for ER, PR and HMB-45; the subepithelial stroma was negative for @entity7 , but muscle-predominant @entity3 was positive for @entity7 . The final histopathological diagnosis was AMLEC.

title: @entity2 with XXXX : a rare entity and review of literature.

answer: @entity6


abstract: What's known on the subject? and What does the study add? The side-effect of targeted agents is known. The clinician should be aware of the side-effects of targeted agents and how to prevent/diminish them, particularly in sequential and combination therapies. The aim of this review is to help physicians tailor targeted treatments for @entity7 to suit @entity0 needs and ensure maximum overall duration of response to therapy by providing a summary of the frequency and time of onset of adverse events (AEs) and by raising awareness of AE profiles. A PubMed literature search was performed, and papers on targeted therapy-related AEs were reviewed. The frequency, severity and management of targeted therapy-related AEs are discussed. Manageable AEs commonly reported with all the approved targeted agents include: fatigue, @entity3 ( @entity2 , @entity4 , @entity5 ), @entity1 , skin and @entity8 . Life-threatening AEs are less common than manageable AEs and are usually class specific. Data suggest that long-term treatment with well-established targeted agents does not result in increased or unexpected AEs. Caution is required with regard to the long-term use of newer targeted agents for which there are no long-term tolerability data or clinical experience. Studies have reported that the type and frequency of observed AEs associated with sequential @entity6 kinase inhibitor (TKI) use are similar to those reported in the literature for TKI monotherapy. Having an awareness of the AE profiles of targeted agents allows the development of effective management strategies. Generally, more extensive clinical experience has accumulated, and AE profiles are more predictable, for well-established targeted agents.

title: Adverse events from targeted therapies in XXXX : the impact on long-term use.

answer: @entity7


abstract: BACKGROUND: Development of neutralizing anti-factor (F)VIII antibodies ('inhibitors') is a serious clinical problem in @entity1 . Increased inhibitor risk has been associated with certain @entity4 missense substitutions, including @entity5 in the A2 domain. OBJECTIVES: The aim of the present study was to identify T-cell epitopes in @entity4 and characterize T-cell responses in two unrelated @entity1 subjects sharing F8- @entity5 and @entity3 *1101 genotypes. We hypothesized that the hemophilic substitution site coincides with an important T-cell epitope. @entity0 /METHODS: The binding affinities of peptides for recombinant HLA-DR proteins were measured and compared with epitope prediction results. CD4+ T cells were stimulated using peptides and stained with fluorescent, peptide-loaded tetramers. RESULTS: The inhibitor subjects, but not HLA-matched controls, had high-avidity @entity3 *1101-restricted T-cell responses against @entity4 (589-608), which contains the hemophilic missense site. Antigen-specific T cells secreted @entity2 and Th2 cytokines and proliferated in response to @entity4 and @entity4 (592-603). @entity4 (589-608) bound with physiologically relevant (micromolar) IC(50) values to recombinant DR0101, DR1101 and DR1501 proteins. CONCLUSIONS: @entity1 @entity0 with @entity5 missense substitutions and these HLA haplotypes had an increased incidence of inhibitors in our cohorts, supporting a paradigm in which presentation of @entity4 epitopes containing the wild-type R593 influences inhibitor risk in this @entity1 sub-population.

title: T-cell responses in two unrelated XXXX inhibitor subjects include an epitope at the factor VIII @entity5 missense site.

answer: @entity1


abstract: BACKGROUND: Development of neutralizing anti-factor (F)VIII antibodies ('inhibitors') is a serious clinical problem in @entity1 . Increased inhibitor risk has been associated with certain @entity4 missense substitutions, including @entity5 in the A2 domain. OBJECTIVES: The aim of the present study was to identify T-cell epitopes in @entity4 and characterize T-cell responses in two unrelated @entity1 subjects sharing F8- @entity5 and @entity3 *1101 genotypes. We hypothesized that the hemophilic substitution site coincides with an important T-cell epitope. @entity0 /METHODS: The binding affinities of peptides for recombinant HLA-DR proteins were measured and compared with epitope prediction results. CD4+ T cells were stimulated using peptides and stained with fluorescent, peptide-loaded tetramers. RESULTS: The inhibitor subjects, but not HLA-matched controls, had high-avidity @entity3 *1101-restricted T-cell responses against @entity4 (589-608), which contains the hemophilic missense site. Antigen-specific T cells secreted @entity2 and Th2 cytokines and proliferated in response to @entity4 and @entity4 (592-603). @entity4 (589-608) bound with physiologically relevant (micromolar) IC(50) values to recombinant DR0101, DR1101 and DR1501 proteins. CONCLUSIONS: @entity1 @entity0 with @entity5 missense substitutions and these HLA haplotypes had an increased incidence of inhibitors in our cohorts, supporting a paradigm in which presentation of @entity4 epitopes containing the wild-type R593 influences inhibitor risk in this @entity1 sub-population.

title: T-cell responses in two unrelated @entity1 inhibitor subjects include an epitope at the factor VIII XXXX missense site.

answer: @entity5


abstract: Botulinum toxin has meanwhile been approved for a number of indications. It is also gaining acceptance in other indications with a major focus on @entity3 . The most common type of @entity0 is @entity4 ( @entity4 ) the pathogenesis of which has not yet been unfolded. As it looks there are vascular, myofascial and supraspinal factors intertwined. It is felt that @entity0 is triggered by myofascial stimuli. The application of botulinum toxin is an intelligent alternative since the favorable effect of pharmacologic and other therapies is limited. Application of BTX should be considered when the pericranial muscles are involved. One of the effects produced lies in the @entity2 , muscular @entity1 and muscle tone. We still don't know whether additional mechanisms such as retrograde uptake and direct antiinflammatory potential are involved. Current data permit the conclusion that headaches are decreased in their frequency and distinctiveness. Significant untoward effects are not to be expected. Neither the ideal dose nor the optimum selection of injection sites have been established as yet, an individual injection scheme is apparently most promising. Injection of the trigger points seems to make sense.

title: [Botulinum toxin in XXXX ].

answer: @entity4


abstract: This case report describes the first reported @entity5 of the dihydropyridine @entity2 channel blocker (CCB) @entity7 . A 49 yr old male presented to the Emergency Department 3 hrs after the ingestion of 560 mg of @entity7 . In the department he had a witnessed @entity1 within 15 minutes of arrival attributed to the @entity5 . Following immediate recovery of consciousness after the @entity1 , he had refractory @entity3 and @entity4 which failed to respond to fluid resuscitation, glucagon therapy, and intravenous @entity2 . He went on to require vasopressor support with noradrenaline and was treated with high dose insulin therapy which was successful in achieving cardiovascular stability. Vasopressor therapy was no longer required within one half life of @entity7 , and the total stay on intensive care was one day before transfer to a ward. @entity2 channel blocker @entity5 is an uncommon but life-threatening @entity5 . Treatment for severe @entity0 is similar to b-blocker @entity5 . @entity3 is treated with intravenous fluid therapy, intravenous @entity2 and possibly glucagon with vasopressor or inotropic support as required. @entity6 is used to attempt reversal of @entity4 . High doses of intravenous insulin with intravenous dextrose as required (hyperinsulinaemic euglycaemia or HIET), has also been successfully reported. Experimental animal data suggests that HIET is of benefit and potentially superior to fluid therapy, @entity2 , glucagon and potentially vasopressor therapy. HIET effectively and sustainably reverses @entity3 , @entity4 and improves myocardial contractility and metabolism. Current advice in @entity2 channel blocker @entity5 is to begin therapy early in @entity0 , starting with a 1.0 IU/kg insulin bolus followed by an infusion of 0.5 IU/kg/hr of insulin and dextrose as required titrated to clinical response.

title: Management of @entity7 XXXX with hyperinsulinaemic euglycaemia therapy: case report.

answer: @entity5


abstract: This case report describes the first reported @entity5 of the dihydropyridine @entity2 channel blocker (CCB) @entity7 . A 49 yr old male presented to the Emergency Department 3 hrs after the ingestion of 560 mg of @entity7 . In the department he had a witnessed @entity1 within 15 minutes of arrival attributed to the @entity5 . Following immediate recovery of consciousness after the @entity1 , he had refractory @entity3 and @entity4 which failed to respond to fluid resuscitation, glucagon therapy, and intravenous @entity2 . He went on to require vasopressor support with noradrenaline and was treated with high dose insulin therapy which was successful in achieving cardiovascular stability. Vasopressor therapy was no longer required within one half life of @entity7 , and the total stay on intensive care was one day before transfer to a ward. @entity2 channel blocker @entity5 is an uncommon but life-threatening @entity5 . Treatment for severe @entity0 is similar to b-blocker @entity5 . @entity3 is treated with intravenous fluid therapy, intravenous @entity2 and possibly glucagon with vasopressor or inotropic support as required. @entity6 is used to attempt reversal of @entity4 . High doses of intravenous insulin with intravenous dextrose as required (hyperinsulinaemic euglycaemia or HIET), has also been successfully reported. Experimental animal data suggests that HIET is of benefit and potentially superior to fluid therapy, @entity2 , glucagon and potentially vasopressor therapy. HIET effectively and sustainably reverses @entity3 , @entity4 and improves myocardial contractility and metabolism. Current advice in @entity2 channel blocker @entity5 is to begin therapy early in @entity0 , starting with a 1.0 IU/kg insulin bolus followed by an infusion of 0.5 IU/kg/hr of insulin and dextrose as required titrated to clinical response.

title: Management of XXXX @entity5 with hyperinsulinaemic euglycaemia therapy: case report.

answer: @entity7


abstract: A 43-year-old @entity0 presented with a widespread @entity2 , which had its onset three months before. The @entity0 had several plaques of active, pigmented, lilac halo disease on the trunk, arms and thighs. A biopsy confirmed that the @entity0 was suffering from @entity2 . Therapy with @entity3 ointment 0.05% was introduced, applied twice a day, 5 days a week. After a month, the ointment failed to significantly improve the lesions. Then the @entity0 was treated with @entity3 ointment in the morning and @entity4 ointment 4 mcg/g in the evening. This combination resulted in marked improvement of the disease after 20 days of therapy, and we decided to stop topical @entity1 . After three months of treatment with topical @entity4 once a day, the plaques regressed considerably and only a very slight pigmentation remained. Therapy was further reduced to one evening, every other day for six months more, and then was suspended completely. No side effects were observed and there was no recurrence at 24-month follow up.

title: Biopsy proven XXXX treated with @entity4 ointment: case report.

answer: @entity2


abstract: A 43-year-old @entity0 presented with a widespread @entity2 , which had its onset three months before. The @entity0 had several plaques of active, pigmented, lilac halo disease on the trunk, arms and thighs. A biopsy confirmed that the @entity0 was suffering from @entity2 . Therapy with @entity3 ointment 0.05% was introduced, applied twice a day, 5 days a week. After a month, the ointment failed to significantly improve the lesions. Then the @entity0 was treated with @entity3 ointment in the morning and @entity4 ointment 4 mcg/g in the evening. This combination resulted in marked improvement of the disease after 20 days of therapy, and we decided to stop topical @entity1 . After three months of treatment with topical @entity4 once a day, the plaques regressed considerably and only a very slight pigmentation remained. Therapy was further reduced to one evening, every other day for six months more, and then was suspended completely. No side effects were observed and there was no recurrence at 24-month follow up.

title: Biopsy proven @entity2 treated with XXXX ointment: case report.

answer: @entity4


abstract: BACKGROUND: The significance of mild elevations in cardiac enzymes after an elective percutaneous coronary intervention (PCI) still remains controversial. We evaluated the significance of @entity1 phosphokinase level (CPK) elevations in a large cohort of @entity0 who had undergone an elective PCI before the IIb/IIIa receptor antagonist era. METHODS: All @entity0 enrolled in the Emory databank from 1981 to 1996 who had an elective PCI were evaluated. We identified 15,637 @entity0 who met our inclusion and exclusion criteria. @entity0 were divided into 4 groups on the basis of the magnitude of the CPK elevation noted in the post-PCI period: group I (CPK <250 mg/dL, n = 14,512); group II (CPK 250-500 mg/dL, n = 715); group III (CPK 500-750 mg/dL, n = 164); and group IV (CPK >750 mg/dL, n = 246). RESULTS: CPK elevations were associated with a significant increase in the periprocedure angiographic complications. Angiographic complication rates were 14.6%, 30.5%, 40.2%, and 43.5% in groups I, II, III, and IV, respectively (P <.001). Long-term survival also correlated inversely with the magnitude of CPK elevations. The 10-year survival rates were 73%, 71%, 69%, and 55% in groups I, II, III, and IV, respectively (P <.0001). After multivariate analysis to correct for clinical factors, a CPK elevation of at least 3-times normal (group IV) was found to be an independent predictor of diminished 30-day and long-term survival (hazard ratio 1.84, 95% CI 1.41-2.41, P <.0001). Elevations in CPK <3-times normal (groups II and III) were not independently predictive of poor long-term survival. CONCLUSION: A CPK level >3-times normal after an elective PCI is a strong independent predictor of poor long-term prognosis.

title: Prognostic implication of XXXX kinase release after elective percutaneous coronary intervention in the pre-IIb/IIIa antagonist era.

answer: @entity1


abstract: This is a retrospective analysis of 188 @entity0 who underwent @entity2 ( @entity2 ) in one or two fractions before bone marrow transplantation (BMT) for a @entity4 . While 139 @entity0 had eye shielding during @entity2 to decrease @entity1 formation, 49 did not. The blocks used for shielding caused cylindrical areas of decreased dose intensity in the brain. The aim of the study was to determine if there was an increased risk of @entity3 or in the CNS after shielding of the eyes. The probability and severity of @entity1 formation with and without shielding were also evaluated. None of the 49 @entity0 without shielding had a relapse in their eyes or in the CNS after BMT. Of the @entity0 with shielding, none had a @entity3 but two of the 139 (1.4%) had a CNS relapse. The incidence of @entity1 without shielding was 90% (19 of 21 evaluable @entity0 ), while with shielding it was 31% (20 of 64). Severe @entity1 were present in eight of 21 (38%) @entity0 without and two of 64 (3%) @entity0 with shielding. The probability of staying @entity1 free for at least five years was 0.77 with and 0.33 without shielding, at 8 years it was 0.53 and 0.24 respectively. The relative risk of developing a @entity1 without shielding vs shielding was three (95% CI=1.5; 5.9). It appears that the incidence of @entity3 and CNS is not increased when the eyes are shielded during @entity2 . Shielding increased the latency time of @entity1 formation and decreased the severity of @entity1 .

title: Eye shielding during XXXX for bone marrow transplantation in @entity0 transplanted for a @entity4 : risks and benefits.

answer: @entity2


abstract: This is a retrospective analysis of 188 @entity0 who underwent @entity2 ( @entity2 ) in one or two fractions before bone marrow transplantation (BMT) for a @entity4 . While 139 @entity0 had eye shielding during @entity2 to decrease @entity1 formation, 49 did not. The blocks used for shielding caused cylindrical areas of decreased dose intensity in the brain. The aim of the study was to determine if there was an increased risk of @entity3 or in the CNS after shielding of the eyes. The probability and severity of @entity1 formation with and without shielding were also evaluated. None of the 49 @entity0 without shielding had a relapse in their eyes or in the CNS after BMT. Of the @entity0 with shielding, none had a @entity3 but two of the 139 (1.4%) had a CNS relapse. The incidence of @entity1 without shielding was 90% (19 of 21 evaluable @entity0 ), while with shielding it was 31% (20 of 64). Severe @entity1 were present in eight of 21 (38%) @entity0 without and two of 64 (3%) @entity0 with shielding. The probability of staying @entity1 free for at least five years was 0.77 with and 0.33 without shielding, at 8 years it was 0.53 and 0.24 respectively. The relative risk of developing a @entity1 without shielding vs shielding was three (95% CI=1.5; 5.9). It appears that the incidence of @entity3 and CNS is not increased when the eyes are shielded during @entity2 . Shielding increased the latency time of @entity1 formation and decreased the severity of @entity1 .

title: Eye shielding during @entity2 for bone marrow transplantation in @entity0 transplanted for a XXXX : risks and benefits.

answer: @entity4


abstract: This is a retrospective analysis of 188 @entity0 who underwent @entity2 ( @entity2 ) in one or two fractions before bone marrow transplantation (BMT) for a @entity4 . While 139 @entity0 had eye shielding during @entity2 to decrease @entity1 formation, 49 did not. The blocks used for shielding caused cylindrical areas of decreased dose intensity in the brain. The aim of the study was to determine if there was an increased risk of @entity3 or in the CNS after shielding of the eyes. The probability and severity of @entity1 formation with and without shielding were also evaluated. None of the 49 @entity0 without shielding had a relapse in their eyes or in the CNS after BMT. Of the @entity0 with shielding, none had a @entity3 but two of the 139 (1.4%) had a CNS relapse. The incidence of @entity1 without shielding was 90% (19 of 21 evaluable @entity0 ), while with shielding it was 31% (20 of 64). Severe @entity1 were present in eight of 21 (38%) @entity0 without and two of 64 (3%) @entity0 with shielding. The probability of staying @entity1 free for at least five years was 0.77 with and 0.33 without shielding, at 8 years it was 0.53 and 0.24 respectively. The relative risk of developing a @entity1 without shielding vs shielding was three (95% CI=1.5; 5.9). It appears that the incidence of @entity3 and CNS is not increased when the eyes are shielded during @entity2 . Shielding increased the latency time of @entity1 formation and decreased the severity of @entity1 .

title: Eye shielding during @entity2 for bone marrow transplantation in XXXX transplanted for a @entity4 : risks and benefits.

answer: @entity0


abstract: PURPOSE: We determined the outcome of minimally symptomatic adult @entity3 in a group of @entity0 treated conservatively with an active surveillance regimen. MATERIALS AND METHODS: A total of 27 @entity0 with asymptomatic or minimally symptomatic @entity3 were treated conservatively. All @entity0 were evaluated with diuretic renograms. @entity3 was defined by an obstructive pattern of the clearance curve and/or T1/2 greater than 20 minutes. Followup consisted of an office visit and renogram every 6 to 12 months. Cases of greater than 10% loss of relative renal function of the affected kidney, development of @entity2 and/or more than 1 episode of acute @entity1 were considered active surveillance failures, and treatment was recommended. RESULTS: Of the 27 @entity0 6 were lost to followup, leaving 21 (median age 47 years) with sufficient followup for analysis. In the 4 @entity0 (19%) who initially presented with mild @entity1 that led to the diagnosis of @entity3 , the @entity1 completely resolved. Ipsilateral relative renal function decreased significantly in 2 @entity0 (9.5%, mean reduction 14%). @entity1 worsened in 3 @entity0 (14.3%) and de novo @entity1 occurred in 1 (4.7%). Surgical intervention for @entity3 was required in 6 @entity0 (29%) at an average of 34 months. In total 15 @entity0 (71%) remained on surveillance with a mean followup of 48 months. CONCLUSIONS: Active surveillance seems to be a reasonable initial option for asymptomatic or mildly symptomatic adult @entity0 with @entity3 because only approximately 30% have progression to surgical intervention within 4 years of diagnosis. This strategy offers the advantage of individualizing therapy according to symptoms and renographic findings.

title: Intermediate term outcomes associated with the surveillance of XXXX in adults.

answer: @entity3


abstract: Ovarian vascular Doppler is a promising screening test for early @entity1 detection. However, disagreements on flow indices used, flow signal shapes and ovarian vessel localization cause continuing controversy. We aimed at clarifying some of this confusion by directly measuring the adnexal arterial blood flow during laparotomy. A 10-MHz continuous Doppler probe was used to examine adnexal vessels in 24 @entity0 undergoing laparotomy for benign gynecological pathology. Resistance (RI) and pulsatility (PI) indices were calculated for each vessel and the shape of the flow signals was noted. The tubal arteries showed a low-velocity flow pattern with relatively high end-diastolic flow when compared to the ovarian artery signals obtained from the infundibulopelvic ligament.The mean RIs for the tubal @entity2 in the infundibulopelvic ligament were 0.59 +/- 0.02 and 0.73 +/- 0.02, respectively. The mean PIs for the @entity2 in the infundibulopelvic ligament were 1.11 +/- 0.09 and 1.53 +/- 0.1, respectively. The tubal artery showed a significantly lower RI and PI when compared to the @entity2 at the infundibulopelvic ligament (p < 0.001 and p = 0.002, respectively) and its hilar branches (p = 0.03 for RI and p = 0.03 for PI). We conclude that tubal artery flow signals, which are measured directly for the first time in this study, are characteristic and are distinct from the ovarian artery signals. Tubal artery signals might be erroneously picked up during transvaginal color Doppler sonography of the ovaries, especially in the presence of conditions causing a decreased impedance to blood flow in the pelvis, such as @entity1 . Recognizing the flow signal from the tubal artery may help in differentiating @entity1 during color Doppler sonography.

title: The characterization of flow signals from XXXX using intraoperative continuous wave Doppler.

answer: @entity2


abstract: Lymphokine-activated killer (LAK) cells are generated in vitro by the incubation of normal @entity2 splenocytes in @entity5 . We have shown previously that the systemic injection of LAK cells in conjunction with recombinant @entity5 can reduce the number of established pulmonary @entity0 in @entity2 . In an attempt to study this approach in the treatment of hepatic @entity0 , we developed a technique for the induction of hepatic @entity0 in @entity2 based on the intrasplenic injection of @entity1 cells and have tested the effects of LAK cells and recombinant @entity5 produced in @entity4 ( @entity6 ) therapy on these @entity0 . Treatment with LAK cells alone in 14 consecutive experiments rarely produced significant reduction in @entity0 over control (mean percentage reduction, 12%). Therapy with @entity6 alone produced a dose-dependent @entity3 . In 20 consecutive experiments when @entity6 was administered i.p. three times a day at doses varying from 1,000 to 5,000, 10,000 to 15,000, and 25,000 units, a statistically significant (P less than 0.05) reduction in liver @entity0 was seen in 2 of 12, 2 of 4, and 8 of 12 determinations, respectively (percentage reduction, 0 to 97; mean, 42%). At doses greater than 25,000 units, the reduction in @entity0 was highly reproducible (percentage reduction, 66 to 95; mean, 83%) and was statistically significant in 14 of 14 determinations. When LAK cells were given i.v. in addition to @entity6 administration in 16 consecutive experiments, the percentage reduction in liver @entity0 was markedly increased over that seen with @entity6 alone (mean percentage reduction, 77% at doses of 5,000 to 25,000 units of @entity6 and mean reduction, 97% for doses greater than 25,000 units of @entity6 ). At doses of 5,000, 10,000, 25,000, and greater than 25,000 units of @entity6 plus LAK cells, significant reduction of liver @entity0 (P less than 0.05) was achieved in 3 of 7, 2 of 2, 8 of 8, and 6 of 6 determinations, respectively. When animals were given fresh splenocytes or splenocytes cultured in complete medium without @entity6 instead of LAK cells, no reduction in liver @entity0 was seen except for that attributable to the administration of @entity6 alone. Sublethal total body irradiation of the @entity2 prior to therapy abrogated the therapeutic effects of @entity6 , but the effects of treatment with LAK cells plus @entity6 were maintained. Thus, treatment with @entity6 alone or in combination with LAK cells is effective in reducing the number of established hepatic micrometastases in a @entity2 model.(ABSTRACT TRUNCATED AT 400 WORDS)

title: Successful immunotherapy of @entity2 experimental hepatic @entity0 with lymphokine-activated killer cells and recombinant XXXX .

answer: @entity5


abstract: Lymphokine-activated killer (LAK) cells are generated in vitro by the incubation of normal @entity2 splenocytes in @entity5 . We have shown previously that the systemic injection of LAK cells in conjunction with recombinant @entity5 can reduce the number of established pulmonary @entity0 in @entity2 . In an attempt to study this approach in the treatment of hepatic @entity0 , we developed a technique for the induction of hepatic @entity0 in @entity2 based on the intrasplenic injection of @entity1 cells and have tested the effects of LAK cells and recombinant @entity5 produced in @entity4 ( @entity6 ) therapy on these @entity0 . Treatment with LAK cells alone in 14 consecutive experiments rarely produced significant reduction in @entity0 over control (mean percentage reduction, 12%). Therapy with @entity6 alone produced a dose-dependent @entity3 . In 20 consecutive experiments when @entity6 was administered i.p. three times a day at doses varying from 1,000 to 5,000, 10,000 to 15,000, and 25,000 units, a statistically significant (P less than 0.05) reduction in liver @entity0 was seen in 2 of 12, 2 of 4, and 8 of 12 determinations, respectively (percentage reduction, 0 to 97; mean, 42%). At doses greater than 25,000 units, the reduction in @entity0 was highly reproducible (percentage reduction, 66 to 95; mean, 83%) and was statistically significant in 14 of 14 determinations. When LAK cells were given i.v. in addition to @entity6 administration in 16 consecutive experiments, the percentage reduction in liver @entity0 was markedly increased over that seen with @entity6 alone (mean percentage reduction, 77% at doses of 5,000 to 25,000 units of @entity6 and mean reduction, 97% for doses greater than 25,000 units of @entity6 ). At doses of 5,000, 10,000, 25,000, and greater than 25,000 units of @entity6 plus LAK cells, significant reduction of liver @entity0 (P less than 0.05) was achieved in 3 of 7, 2 of 2, 8 of 8, and 6 of 6 determinations, respectively. When animals were given fresh splenocytes or splenocytes cultured in complete medium without @entity6 instead of LAK cells, no reduction in liver @entity0 was seen except for that attributable to the administration of @entity6 alone. Sublethal total body irradiation of the @entity2 prior to therapy abrogated the therapeutic effects of @entity6 , but the effects of treatment with LAK cells plus @entity6 were maintained. Thus, treatment with @entity6 alone or in combination with LAK cells is effective in reducing the number of established hepatic micrometastases in a @entity2 model.(ABSTRACT TRUNCATED AT 400 WORDS)

title: Successful immunotherapy of @entity2 experimental hepatic XXXX with lymphokine-activated killer cells and recombinant @entity5 .

answer: @entity0


abstract: Lymphokine-activated killer (LAK) cells are generated in vitro by the incubation of normal @entity2 splenocytes in @entity5 . We have shown previously that the systemic injection of LAK cells in conjunction with recombinant @entity5 can reduce the number of established pulmonary @entity0 in @entity2 . In an attempt to study this approach in the treatment of hepatic @entity0 , we developed a technique for the induction of hepatic @entity0 in @entity2 based on the intrasplenic injection of @entity1 cells and have tested the effects of LAK cells and recombinant @entity5 produced in @entity4 ( @entity6 ) therapy on these @entity0 . Treatment with LAK cells alone in 14 consecutive experiments rarely produced significant reduction in @entity0 over control (mean percentage reduction, 12%). Therapy with @entity6 alone produced a dose-dependent @entity3 . In 20 consecutive experiments when @entity6 was administered i.p. three times a day at doses varying from 1,000 to 5,000, 10,000 to 15,000, and 25,000 units, a statistically significant (P less than 0.05) reduction in liver @entity0 was seen in 2 of 12, 2 of 4, and 8 of 12 determinations, respectively (percentage reduction, 0 to 97; mean, 42%). At doses greater than 25,000 units, the reduction in @entity0 was highly reproducible (percentage reduction, 66 to 95; mean, 83%) and was statistically significant in 14 of 14 determinations. When LAK cells were given i.v. in addition to @entity6 administration in 16 consecutive experiments, the percentage reduction in liver @entity0 was markedly increased over that seen with @entity6 alone (mean percentage reduction, 77% at doses of 5,000 to 25,000 units of @entity6 and mean reduction, 97% for doses greater than 25,000 units of @entity6 ). At doses of 5,000, 10,000, 25,000, and greater than 25,000 units of @entity6 plus LAK cells, significant reduction of liver @entity0 (P less than 0.05) was achieved in 3 of 7, 2 of 2, 8 of 8, and 6 of 6 determinations, respectively. When animals were given fresh splenocytes or splenocytes cultured in complete medium without @entity6 instead of LAK cells, no reduction in liver @entity0 was seen except for that attributable to the administration of @entity6 alone. Sublethal total body irradiation of the @entity2 prior to therapy abrogated the therapeutic effects of @entity6 , but the effects of treatment with LAK cells plus @entity6 were maintained. Thus, treatment with @entity6 alone or in combination with LAK cells is effective in reducing the number of established hepatic micrometastases in a @entity2 model.(ABSTRACT TRUNCATED AT 400 WORDS)

title: Successful immunotherapy of XXXX experimental hepatic @entity0 with lymphokine-activated killer cells and recombinant @entity5 .

answer: @entity2


abstract: BACKGROUND: The management of @entity0 with @entity2 ( @entity2 ), primary @entity7 (pICH) and primary @entity3 (pSAH) remains a highly demanding challenge in critical care medicine. Antithrombotic agents are one of the most relevant risk factors for poor outcome. However, in the acute setting of @entity6 , information on preexisting medication might not be available. This group of @entity0 is insufficiently characterized regarding pharmacologically induced @entity5 . METHODS: We retrospectively analyzed consecutive @entity0 with @entity2 , pICH and pSAH admitted to our department with unknown preexisting medication. The impact of @entity1 and @entity4 -receptor antagonists on platelet function was tested via the Multiplate analyzer. @entity0 ' characteristics, management and the influence of @entity5 on outcome were evaluated. RESULTS: Within 25  months 103 @entity0 with @entity2 (61), pICH (32) or pSAH (10) and unknown antithrombotic medication were admitted to our department. In 54 (52.4  %) of the @entity0 reduced platelet function was detected, mainly caused by @entity1 . In the @entity2 group, 30 @entity0 (49.2  %) were identified, while Multiplate analysis detected @entity5 in 19 (59.4  %) subjects in the pICH group and 5 in the pSAH group (50  %). In multivariable analysis the pathological Multiplate result was not associated with worse outcome; however, in our cohort 47 (87  %) @entity0 received hemostatic therapy following detection of impaired platelet function. CONCLUSION: Our results demonstrate the high frequency of pharmacologically impaired platelet function in @entity0 with unknown preexisting medication. Early assessment of platelet function is an important tool to allow optimized treatment in these @entity0 .

title: High prevalence of pharmacologically induced XXXX in the acute setting of @entity6 .

answer: @entity5


abstract: BACKGROUND: The management of @entity0 with @entity2 ( @entity2 ), primary @entity7 (pICH) and primary @entity3 (pSAH) remains a highly demanding challenge in critical care medicine. Antithrombotic agents are one of the most relevant risk factors for poor outcome. However, in the acute setting of @entity6 , information on preexisting medication might not be available. This group of @entity0 is insufficiently characterized regarding pharmacologically induced @entity5 . METHODS: We retrospectively analyzed consecutive @entity0 with @entity2 , pICH and pSAH admitted to our department with unknown preexisting medication. The impact of @entity1 and @entity4 -receptor antagonists on platelet function was tested via the Multiplate analyzer. @entity0 ' characteristics, management and the influence of @entity5 on outcome were evaluated. RESULTS: Within 25  months 103 @entity0 with @entity2 (61), pICH (32) or pSAH (10) and unknown antithrombotic medication were admitted to our department. In 54 (52.4  %) of the @entity0 reduced platelet function was detected, mainly caused by @entity1 . In the @entity2 group, 30 @entity0 (49.2  %) were identified, while Multiplate analysis detected @entity5 in 19 (59.4  %) subjects in the pICH group and 5 in the pSAH group (50  %). In multivariable analysis the pathological Multiplate result was not associated with worse outcome; however, in our cohort 47 (87  %) @entity0 received hemostatic therapy following detection of impaired platelet function. CONCLUSION: Our results demonstrate the high frequency of pharmacologically impaired platelet function in @entity0 with unknown preexisting medication. Early assessment of platelet function is an important tool to allow optimized treatment in these @entity0 .

title: High prevalence of pharmacologically induced @entity5 in the acute setting of XXXX .

answer: @entity6


abstract: UNASSIGNED: Considerable evidence demonstrates that @entity2 are prevalent in @entity4 during both acute @entity9 and euthymia. However, it is less clear whether these cognitive disturbances are state- or trait-related. We here present the first longitudinal study employing a within-subject pre- and post-testing examining acutely admitted bipolar @entity0 (BP) in @entity5 or @entity4 and during euthymia, aiming to identify cognitive performance from acute illness to remission. Cognitive performance was measured during acute @entity9 and repeated after at least 3  months of remission. To do so, 55 BP (35 @entity5 , 20 hypo-/ @entity4 ) and 55 healthy controls (HC) were tested with a neuropsychological test battery (attention, working memory, verbal memory, executive functioning). The results showed @entity3 in acutely ill BP compared to HC: @entity5 @entity0 showed a characteristic @entity7 , while @entity4 @entity0 had severe deficits in executive functioning. Twenty-nine remitted BP could be measured in the follow-up (dropout rate 48  %), whose cognitive functions partially recovered, whereas working @entity8 were still impaired. However, we found that subthreshold @entity5 and persisting @entity1 in euthymic BP were associated with reduced speed, @entity8 , while working memory was correlated with @entity6 (lifetime). This result indicates working memory as trait related for a subgroup of BP with @entity6 . In contrast, attention and verbal memory are negatively influenced by state factors like residual symptoms, which should be more considered as possible confounders in the search of cognitive endophenotypes in remitted BP.

title: @entity3 in XXXX : from acute episode to remission.

answer: @entity4